Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Trainings > Topics > Flashcards

Topics Flashcards

1
Q

Treatment Considerations in Polycythemia Vera and Myelofibrosis: A Real-World Patient Case Discussion

A

Branded Combo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Intervening with Jakafi® (ruxolitinib) to Achieve Durable Count Control: Real-World Patient Case Discussion

A

Branded PV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Intervening With Jakafi® (ruxolitinib) at Diagnosis in Patients With Intermediate- or High-Risk Myelofibrosis | A Real World Patient Case Discussion

A

Branded MF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Consider Jakafi ® (ruxolitinib) At the First Sign of Steroid-Refractory Acute GVHD

A

GVHD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Intervening With Jakafi® (ruxolitinib) to Achieve Durable Count Control—Focus on Adults With Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea

A

Virtual Abridged Branded PV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Intervening With Jakafi® (ruxolitinib) at Diagnosis in Patients With Intermediate- or High-Risk Myelofibrosis

A

Virtual Abridged Branded MF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

AN IN-DEPTH REVIEW:

Long-Term Findings From COMFORT-II, a Phase 3 Study of Ruxolitinib vs Best Available Therapy for Myelofibrosis

A

Journal Article Review: COMFORT 5 year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

AN IN-DEPTH REVIEW:

Ruxolitinib Versus Standard Therapy for the Treatment of Polycythemia Vera

A

Journal Article Review: Response 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q 
AN IN-DEPTH REVIEW:
Ruxolitinib for the treatment of
inadequately controlled polycythemia
vera without splenomegaly
(RESPONSE-2) a Randomised Open-Label, Phase 3b Study
A

Journal Article Review: Response 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Identifying Patients With Clinical Characteristics of Advanced Polycythemia Vera— Real-World Patient Case Discussion

A

Unbranded PV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Identifying Patients With Clinical Characteristics of Advanced Polycythemia Vera

A

Virtual Abridged Unbranded PV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Intervening With Ruxolitinib at Diagnosis in Patients With Intermediate- or High-Risk Myelofibrosis - Real-World Patient Case Discussion

A

Inst. Branded MF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Intervening With Ruxolitinib to Achieve Durable Count Control: Real-World Patient Case Discussion - Focus on Adults With Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea

A

Inst. Branded PV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

AN IN-DEPTH REVIEW OF THE REACH2 STUDY PUBLICATION: Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

A

Journal Article Review: REACH2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q 
AN IN-DEPTH REVIEW:
Long-Term Efficacy and Safety of
Ruxolitinib Versus Best Available Therapy
in Polycythaemia Vera (RESPONSE):
5-Year Follow Up of a Phase 3 Study
A

Journal Article Review: RESPONSE 5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Identifying Patients With Clinical Characteristics of Advanced Polycythemia Vera— Real-World Patient Case Discussion

A

Inst. Unbranded PV

17
Q

PEMAZYRE® (pemigatinib): The First and Only FDA-Approved Treatment for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma (CCA) with an FGFR2 Fusion or Rearrangement

A

PEMAZYRE

18
Q

Monjuvi (tafasitamab-cxix) for Use as Second-Line Therapy in Adult Patients with R/R DLBCL, in Combination with Lenalidomide

A

Monjuvi

19
Q

Consider Jakafi® (ruxolitinib) At the First Sign of Steroid-Refractory Acute GVHD In adult and pediatric patients 12 years and older”

A

ABR GVHD

20
Q

Intervening With Ruxolitinib at Diagnosis in Patients With Intermediate- or High-Risk Myelofibrosis | Real-World Patient Case Discussion

A

Thyne - Branded MF

21
Q

Intervening With Ruxolitinib to Achieve Durable Count Control: Real-World Patient Case Discussion - Focus on Adults With Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea

A

Thyne - Branded PV

22
Q

Monitoring Patients With Polycythemia Vera for Potential Characteristics of Disease Progression— Real-World Patient Case Discussion

A

Thyne - Unbranded PV

Trainings (5 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions